Yissum Ltd. Introduces Novel Markers for Brain Cancer Survival Prognosis and a New Treatment Method for the Disease

JERUSALEM--(BUSINESS WIRE)--Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, announced today that a research team led by Dr. Rotem Karni and the post-doctoral researcher Dr. Regina Golan-Gerstel from the Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel-Canada, at the Hebrew University School of Medicine, discovered novel biomarkers for predicting survival of patients with glioblastoma, the most common and deadliest of brain cancers, as well as a novel method for treating the disease. The research was published in the July issue of Cancer Research (http://cancerres.aacrjournals.org/content/71/13/4464.full). The invention was patented by Yissum, who is currently exploring potential partners for further development.

Back to news